Indivior PLC Indivior Responds to Letter from Oaktree
November 08 2024 - 2:00AM
RNS Regulatory News
RNS Number : 4443L
Indivior PLC
08 November 2024
Indivior Responds to Publication of a Letter
by Oaktree Capital Management to the Board of
Indivior
Richmond, VA, November 8, 2024 - Indivior PLC (NASDAQ
/ LSE: INDV) the Board of Directors (the "Board")
of Indivior plc ("Indivior" or the "Company") notes the publication
today of a letter from Oaktree Capital Management LP ("Oaktree") to
the Board of Indivior.
The Board has engaged actively with
Oaktree in recent weeks on these topics, and remains open-minded
about all proposals to enhance value creation. The Board is focused
on acting in the best interests of all shareholders as we continue
to execute on our strategy.
Indivior looks forward
to further engagement with Oaktree and other
shareholders.
About
Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD), overdose and
serious mental illnesses. Our vision is that all patients around
the world will have access to evidence-based treatment for the
chronic conditions and co-occurring disorders of SUD. Indivior is
dedicated to transforming SUD from a global human crisis to a
recognized and treated chronic disease. Building on its global
portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category
and potentially address other chronic conditions and co-occurring
disorders of SUD. Headquartered in the United States in Richmond,
VA, Indivior employs over 1,000 individuals globally and its
portfolio of products is available in over 30 countries worldwide.
Visit
www.indivior.com to learn more. Connect
with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior.
For Further
Information
Investor Enquiries
|
Jason Thompson
|
VP, Investor Relations
Indivior PLC
|
+1 804 402 7123
jason.thompson@indivior.com
|
|
Tim Owens
|
Director, Investor Relations
Indivior PLC
|
+1 804 263 3978
timothy.owens@indivior.com
|
Media Enquiries
|
Jonathan Sibun
|
Teneo
U.S. Media Inquiries
|
+44 (0)20 7353 4200
+1 804 594 0836
Indiviormediacontacts@indivior.com
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RSPFSUEDWELSEFF
Indivior (LSE:INDV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Indivior (LSE:INDV)
Historical Stock Chart
From Dec 2023 to Dec 2024